Posted by Michael Wonder on 17 Sep 2018
FDA grants rare paediatric disease designation to Cellectar Biosciences’ CLR 131 for the treatment of osteosarcoma
17 September 2018 - Cellectar Biosciences announces today that the U.S. FDA has granted rare paediatric disease designation to CLR 131 for the treatment of osteosarcoma, a rare paediatric cancer.
CLR 131 is Cellectar’s lead phospholipid drug conjugate product candidate.
Since May 2018 the company has received rare paediatric disease designation for CLR 131 in four paediatric cancers: neuroblastoma, rhabdomyosarcoma, Ewing’s Sarcoma and, most recently, osteosarcoma.
